References(41)
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here?Cancer. 2015;121(5):664–72.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441–64.
Kalemkerian GP, Schneider BJ. Advances in small cell lung cancer. Hematol Oncol Clin North Am. 2017;31(1):143–56.
Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21(5):821–33.
Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the Checkmate 032 randomized cohort. J Thorac Oncol. 2020;15(3):426–35.
Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, et al. Comparative effectiveness of nivolumab versus standard of care for third‐line patients with small‐cell lung cancer. J Comp Eff Res. 2020;9(18):1275–84.
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second‐line nivolumab in relapsed small‐cell lung cancer: Checkmate 331☆. Ann Oncol. 2021;32(5):631–41.
Warner AB, Postow MA. Bigger is not always better: tumor size and prognosis in advanced melanoma. Clin Cancer Res. 2018;24(20):4915–17.
Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, et al. A nomogram to predict survival in non‐small cell lung cancer patients treated with nivolumab. J Transl Med. 2019;17(1):99.
Hermes A, Gatzemeier U, Waschki B, Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer—a retrospective single institution analysis. Respir Med. 2010;104(12):1937–42.
Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4(4):617–20.
Chung HC, Piha‐Paul SA, Lopez‐Martin J, Schellens J, Kao S, Miller WH Jr, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE‐028 and KEYNOTE‐158 studies. J Thorac Oncol. 2020;15(4):618–27.
Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peter S, et al. Nivolumab and ipilimumab as maintenance therapy in extensive‐disease small‐cell lung cancer: checkmate 451. J Clin Oncol. 2021;39(12):1349–59.
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–96.
Russ AJ, Wentworth L, Xu K, Rakhmilevich A, Seroogy CM, Sondel PM, et al. Suppression of T‐cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011;18(13):3848–57.
Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra352.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med. 2020;12(535):eaaz8235.
Salas‐Benito D, Pérez‐Gracia JL, Ponz‐Sarvisé M, Rodriguez‐Ruiz ME, Martínez‐Forero I, Castañón E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353–67.
Reck M, Luft A, Szczesna A, Havel L, Kim S‐W, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive‐stage small‐cell lung cancer. J Clin Oncol. 2016;34(31):3740–48.
Blair HA. Atezolizumab: a review in previously treated advanced non‐small cell lung cancer. Target Oncol. 2018;13(3):399–407.
Ishii H, Azuma K, Kawahara A, Kinoshita T, Kage M, Hoshino T, et al. Significance of programmed cell death‐ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10(3):426–30.
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and pd‐l1 subgroup analysis of patients with extensive‐stage small‐cell lung cancer treated with atezolizumab, carboplatin, and etoposide (impower133). J Clin Oncol. 2021;39(6):619–30.
Paz‐Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum‐etoposide versus platinum‐etoposide in first‐line treatment of extensive‐stage small‐cell lung cancer (CASPIAN): a randomised, controlled, open‐label, phase 3 trial. Lancet. 2019;394(10212):1929–39.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum‐etoposide versus platinum‐etoposide alone in first‐line treatment of extensive‐stage small‐cell lung cancer (CASPIAN): updated results from a randomised, controlled, open‐label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non‐small‐cell lung cancer. N Engl J Med. 2017;377(20):1919–29.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first‐line therapy for extensive‐stage small‐cell lung cancer: randomized, double‐blind, phase III KEYNOTE‐604 study. J Clin Oncol. 2020;38(21):2369–79.
Giaj Levra M, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non‐small cell lung cancer in the real‐world setting: a national data base analysis. Lung Cancer. 2020;140:99–106.
Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, et al. Anti‐angiogenic therapy in cancer: downsides and new pivots for precision medicine. Front Pharmacol. 2016;7:519.
Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune‐vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195–203.
Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, et al. Camrelizumab plus apatinib in extensive‐stage SCLC (PASSION): a multicenter, two‐stage, phase 2 trial. J Thorac Oncol. 2021;16(2):299–309.
Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, et al. AMG 757, a half‐life extended, DLL3‐targeted bispecific t‐cell engager, shows high potency and sensitivity in preclinical models of small‐cell lung cancer. Clin Cancer Res. 2021;27(5):1526–37.
Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second‐line therapy in DLL3‐high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol.2021;16(9):1547–58.
Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, et al. Enhanced AC133‐specific Car T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2021;520:385–99.
Chen X, Amar N, Zhu Y, Wang C, Xia C, Yang X, et al. Combined DLL3‐targeted bispecific antibody with pd‐1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020;8(1):e000785.
Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, et al. Expression of PD‐1 and PD‐L1 on tumor‐infiltrating lymphocytes predicts prognosis in patients with small‐cell lung cancer. Onco Targets Ther. 2020;13:6475–83.
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289–97.
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346–60.
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co‐occurring genomic alterations define major subsets of KRAS‐mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery. 2015;5(8):860–77.
Wang Z, Zhao J, Ma Z, Cui J, Shu Y, Liu Z, et al. A phase 2 study of tislelizumab in combination with platinum‐based chemotherapy as first‐line treatment for advanced lung cancer in Chinese patients. Lung Cancer. 2020;147:259–68.